Our Lady Of Lourdes Hospital
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
The dermatology unit at Our Lady Of Lourdes Hospital is focusing on innovative treatments for chronic skin conditions, aiming to improve patient outcomes and quality of life.
- Evaluation of lutikizumab for moderate‑to‑severe hidradenitis suppurativa
- Phase 2 study of LAD191 in adults with hidradenitis suppurativa
- Assessment of multiple dosing regimens of LAD191 for safety and efficacy
With a total of twelve active trials and nine investigators, the department is advancing targeted therapy research for skin and connective tissue diseases.
Respiratory Tract Diseases
Researchers are evaluating novel biologics and small molecules to reduce exacerbations and improve lung function in patients with chronic obstructive pulmonary disease and eosinophilic asthma.
- Benralizumab add‑on therapy for eosinophilic asthma uncontrolled on standard inhalers
- Tozorakimab combined with standard care to lower COPD exacerbation rates
- Verekitug assessment for better COPD control
- MTX‑463 trial evaluating forced vital capacity in idiopathic pulmonary fibrosis
The site’s respiratory research program integrates safety and efficacy endpoints to address unmet needs in lung disease management.
Immune System Diseases
The clinical portfolio includes studies that modulate immune pathways to treat gastrointestinal autoimmune conditions and systemic inflammation.
- KAN‑101 trial measuring duodenal histology improvements in celiac disease
- Risankizumab versus vedolizumab comparison in moderate‑to‑severe ulcerative colitis
- Targeted therapy evaluation for moderate to severe Crohn’s disease
By exploring both established and emerging biologics, the hospital aims to deliver safer, more effective options for immune‑mediated disorders.
Digestive System Diseases
Clinical investigations are centered on inflammatory bowel disease and postoperative infection prevention, seeking to enhance digestive health outcomes.
- D‑PLEX administered with standard care to prevent post‑abdominal surgery incisional infection
- Study of targeted therapies for moderate to severe Crohn’s disease
- Comparative efficacy of biologics in ulcerative colitis patients naïve to targeted treatment
The department leverages multidisciplinary expertise to address both chronic and acute digestive conditions within the Irish patient community.
Bacterial Infections and Mycoses
Focused on combating resistant bacterial threats, the team evaluates anti‑infective agents to reduce recurrence and surgical site infections.
- VE303 trial assessing recurrence reduction in Clostridioides difficile infection
- D‑PLEX study for prevention of surgical site infection following abdominal procedures
- Anti‑infective efficacy assessment of novel agents alongside standard of care
With a collaborative approach, Our Lady Of Lourdes Hospital contributes to the development of safer antimicrobial strategies across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Our Lady Of Lourdes Hospital
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary Fibrosis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Yet Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 3 | Unknown | 2024-04-30 | 2025-12-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.